Skip to main content

Table 2 Availability of anti-malarials (provider survey) (cluster summaries from the 9 intervention and 9 control clusters)

From: The effect of an anti-malarial subsidy programme on the quality of service provision of artemisinin-based combination therapy in Kenya: a cluster-randomized, controlled trial

Availability of anti-malarials:

Control% (SD) n/d

Intervention% (SD) n/d

Difference in means (95%CI)

P value Unadjusted Adjusted

Any AL (unexpired):

    

   Baseline

0.5 (1.2) 2/263

1.5 (3.2) 3/205

  

   Follow up

5.2 (4.0) 18/319

36.8 (13.1) 117/320

31.7 (22.0, 41.3)

0.0001 0.00011

   Tibamal trained

-

65.7 (16.1) 103/154

  

   Tibamal trained & job aid

-

76.8 (32.4) 50/62

  

Tibamal (unexpired):

    

   Baseline

-

-

  

   Follow up

0 (0) 0/319

35.1 (12.3) 111/320

35.1 (26.4, 43.8)

0.0001 0.00012

   Tibamal trained

-

65.3 (15.6) 102/154

  

   Tibamal trained & job aid

-

76.8 (32.4) 50/62

  

Other ACT:

    

   Baseline

0.8 (1.6) 2/263

0 (0) 0/205

  

   Follow up

2.1 (2.8) 7/319

0.4 (1.1) 1/320

−1.7 (−3.9, 0.4)

0.1058 0.05802

   Tibamal trained

-

0.5 (1.6) 1/154

  

   Tibamal trained & job aid

-

1.1 (3.3) 1/62

  

Non-ACT therapy:

    

   Baseline

52.8 (12.0) 140/263

63.7 (10.4) 130/205

  

   Follow up

39.6 (10.0) 128/319

40.0 (5.5) 127/320

0.4 (−7.6, 8.5)

0.9082 0.51873

   Tibamal trained

-

54.3 (13.5) 80/154

  

   Tibamal trained & job aid

-

53.8 (28.1) 35/62

  
  1. n numerator, d denominator, SD standard deviation, CI confidence interval.
  2. 1 adjusted for distance to nearest road; 2 adjusted for outlet type and district; 3 adjusted for outlet type, distance to nearest road and clinical training.